Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
(WorldNews Japan)

PRESS RELEASE Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials Dosing of first subject in clinical trial by Pfizer triggers $5 million payment to Sosei Heptares Clinical development candidate is an oral, small molecule modulator of an undisclosed G protein-coupled receptor (GPCR) target Eighth GPCR-targeted drug candidate to enter clinical development originating from Sosei Heptares` StaR® technology/SBDD platform Tokyo, Japan and Cambridge, UK, 28 September 2020 - Sosei Group Corporation ("the Company"; TSE: 4565) has been notified by Pfizer that the first subject in a clinical...